Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder

[1] Abecasis GR(2010)A map of human genome variation from population-scale sequencing Nature 467 1061-1073

[2] Altshuler D(2003)Successful amplification of extremely GC-rich promoter regions using a novel ‘slowdown PCR’ technique Pharmacogenetics 13 759-766

[3] Auton A(2007)The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients Clin Cancer Res 13 5790-5797

[4] Brooks LD(2011)Regulatory BCL2 promoter polymorphism (938C>A) is associated with adverse outcome in patients with prostate carcinoma Int J Cancer 29 2390-2399

[5] Durbin RM(1996)Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance Cancer 77 255-264

[6] Gibbs RA(2005)Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 263-265

[7] Hurles ME(1999)Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2 Int J Cancer 84 545-552

[8] McVean GA(2002)The Bcl2 family: regulators of the cellular life-or-death switch Nature reviews Cancer 2 647-656

[9] Bachmann HS(2001)The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma J Urol 166 1098-1105

[10] Siffert W(2008)Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia Cancer Res 68 10178-10186

[1] Abecasis GR(2010)A map of human genome variation from population-scale sequencing Nature 467 1061-1073

[2] Altshuler D(2003)Successful amplification of extremely GC-rich promoter regions using a novel ‘slowdown PCR’ technique Pharmacogenetics 13 759-766

[3] Auton A(2007)The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients Clin Cancer Res 13 5790-5797

[4] Brooks LD(2011)Regulatory BCL2 promoter polymorphism (938C>A) is associated with adverse outcome in patients with prostate carcinoma Int J Cancer 29 2390-2399

[5] Durbin RM(1996)Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance Cancer 77 255-264

[6] Gibbs RA(2005)Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 263-265

[7] Hurles ME(1999)Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2 Int J Cancer 84 545-552

[8] McVean GA(2002)The Bcl2 family: regulators of the cellular life-or-death switch Nature reviews Cancer 2 647-656

[9] Bachmann HS(2001)The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma J Urol 166 1098-1105

[10] Siffert W(2008)Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia Cancer Res 68 10178-10186